Phaseline

Companies › Newish Biotech (Wuxi)

Newish Biotech (Wuxi): clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NWRD08
HPV-16/HPV-18 therapeutic vaccine (plasmid DNA)
–Phase 2High-grade Squamous Intraepithelial Lesion (HSIL)May 2027
NWRD09
HPV-16 targeted mRNA therapeutic vaccine
–Phase 1Persistent HPV16 Infection; High-grade Squamous Intraepithelial Lesion (HSIL)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07710664NWRD09Phase 1Persistent HPV16 InfectionInfectious diseaseDec 2026
NCT07047989NWRD09Phase 1High-grade Squamous Intraepithelial Lesion (HSIL)OncologyDec 2026
NCT07175662NWRD08Phase 2High-grade Squamous Intraepithelial Lesion (HSIL)OncologyMay 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

ImmuneOncia Therapeutics Huahui Health Tianjin ConjuStar Biologics Lantheus Medical Imaging Zhejiang Hisun Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.